Biodesix (BDSX) Cash & Equivalents (2019 - 2026)

Biodesix (BDSX) has 8 years of Cash & Equivalents data on file, last reported at $25.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 45.27% year-over-year to $25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.6 million (up 45.27% YoY) and the FY2025 annual result came in at $19.0 million, down 27.65% from the prior year.
• Cash & Equivalents climbed to $25.6 million in Q1 2026, from $19.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $43.1 million in Q4 2022 to a low of $11.5 million in Q1 2024.
• A 5-year average of $23.4 million and a median of $20.7 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 70.36% — and 2024, when it soared 142.51%.
• Tracing BDSX's Cash & Equivalents over 5 years: stood at $43.1 million in 2022, then sank by 39.0% to $26.3 million in 2023, then slipped by 0.15% to $26.2 million in 2024, then declined by 27.65% to $19.0 million in 2025, then jumped by 34.68% to $25.6 million in 2026.
• The last three Cash & Equivalents figures came in at $25.6 million (Q1 2026), $19.0 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.